Immunogenicity And Safety Of Acellular Pertussis Vaccine At Birth
Funder
National Health and Medical Research Council
Funding Amount
$1,508,927.00
Summary
Currently, the first dose of a vaccine to protect against pertussis (whooping cough) is not given until 2 months of age, and third dose until 6 months. However, more than 80% of the most severe cases of pertussis (resulting in hospitalisation or death) occur before 6 months. This study aims to show that giving the first dose of pertussis vaccine at birth and the second dose at 6 weeks protects babies at the time they are most likely to die or become severely ill from whooping cough
Treatment Of Asymptomatic Candidiasis In Pregnant Women For The Prevention Of Preterm Birth: A Randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,120,373.00
Summary
Being born too early is a leading cause of perinatal death and morbidity. This trial seeks to determine whether screening for and treating candidiasis in pregnancy reduces the risk of this serious health problem. The trial will discover whether a simple treatment in pregnancy can reduce preterm birth. If positive, the results will be relevant to the management of every pregnancy.